SEC Form 4 · accession 0001415889-16-006513
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry Jemil Esber
Director
Period of report
Apr 1, 2016
Accepted (ET)
Jul 15, 2016 · 9:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | — | Apr 1, 2016 | A | 89,419 | A | Apr 14, 2016 | Apr 1, 2026 | Common Stock | 89,419 | 747,815 | D |
| Restricted Stock UnitsF1 | — | Apr 1, 2016 | A | 27,650 | A | Jul 1, 2016 | Jul 1, 2026 | Common Stock | 27,650 | 775,465 | D |
Explanation of responses
- F1Each restricted stock unit represents the right to receive, at settlement, one share of common stock.